gene

IDE

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about IDE: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

254Connections

30Hypotheses

1Analyses

50Outgoing

50Incoming

14Experiments

1Debates

Summary

IDE is a gene implicated in neurodegeneration research. Key relationships include: activates, regulates, associated with. Associated with Als, Alzheimer, Carcinoma. Connected to 35 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	IDE
Aliases	Page for IDE Gene
Chromosome	10q23.33
Protein Type	Protease
Function	Peptide hydrolysis, amyloid clearance
Molecular Weight	110 kDa
Amino Acids	1019 aa
Pathways	Oxidative Stress
NCBI Gene ID	3416
GeneCards	IDE
Human Protein Atlas	IDE
Amyloid-beta degradation	Primary enzyme responsible for clearing Abeta in the brain
Insulin metabolism	Regulates insulin signaling through peptide degradation
Proteostasis	Maintains cellular protein quality control
Disease associations	Alzheimer's disease, Parkinson's disease, Type 2 diabetes
Associated Diseases	Als, Alzheimer, Alzheimer's disease, Diabetes, Insulin Resistance
Known Drugs/Compounds	metformin
Interactions	ACE, ACE2, AD, ADAM10, AKT, ALZHEIMER
SciDEX Hypotheses	Personalized Microbiome Restoration Based on Indiv
KG Connections	254 knowledge graph edges
Databases	GeneCards UniProt HPA STRING

Wiki Pages (6)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    IDE["IDE"]
    Fibrosis{"Fibrosis"}
    IDE -->|"activates"| Fibrosis
    Hepatitis{"Hepatitis"}
    IDE -->|"activates"| Hepatitis
    Carcinoma{"Carcinoma"}
    IDE -->|"activates"| Carcinoma
    Cirrhosis{"Cirrhosis"}
    IDE -->|"activates"| Cirrhosis
    Inflammation{"Inflammation"}
    IDE -->|"activates"| Inflammation
    Ms{"Ms"}
    IDE -->|"activates"| Ms
    Diabetes{"Diabetes"}
    IDE -->|"associated with"| Diabetes
    Alzheimer{"Alzheimer"}
    IDE -->|"associated with"| Alzheimer
    CD36["CD36"]
    IDE -->|"activates"| CD36
    Er_Stress(["Er Stress"])
    IDE -->|"activates"| Er_Stress
    Unfolded_Protein_Response(["Unfolded Protein Response"])
    IDE -->|"activates"| Unfolded_Protein_Response
    Oxidative_Stress(["Oxidative Stress"])
    IDE -->|"activates"| Oxidative_Stress
    CD36 -->|"activates"| IDE
    INFLAMMATION["INFLAMMATION"]
    INFLAMMATION -->|"activates"| IDE
    OXIDATIVE_STRESS["OXIDATIVE STRESS"]
    OXIDATIVE_STRESS -->|"activates"| IDE
    style IDE fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (155)

Target	Relation	Type	Str
amyloid-beta	degrades	protein	0.90
Alzheimer	associated_with	disease	0.85
AMYLOID BETA	degrades	protein	0.80
NEP	regulates	gene	0.70
NEP	degrades	gene	0.70
LDLR	regulates	gene	0.70
STING	inhibits	gene	0.70
PSEN1	expresses	gene	0.70
MAPT	regulates	gene	0.70
PSEN2	regulates	gene	0.70
NRF2	activates	gene	0.70
NEP	expressed_in	gene	0.70
NEURONS	expresses	cell_type	0.70
MAPT	expresses	gene	0.70
PLP1	regulates	gene	0.70
oxidative stress response	participates_in	pathway	0.70
ALZHEIMER'S DISEASE	associated_with	gene	0.70
ALZHEIMER	associated_with	gene	0.70
Carcinoma	activates	disease	0.65
Diabetes	associated_with	disease	0.65
Ms	activates	disease	0.65
Inflammation	activates	disease	0.65
Cirrhosis	activates	disease	0.65
Hepatitis	activates	disease	0.65
Fibrosis	activates	disease	0.65
Neuroinflammation	activates	disease	0.65
ALS	inhibits	disease	0.65
ALS	expressed_in	disease	0.65
Neurodegeneration	activates	disease	0.65
ALS	activates	disease	0.65
Ischemia	regulates	disease	0.65
Als	associated_with	disease	0.65
Stroke	regulates	disease	0.65
Neurodegeneration	regulates	disease	0.65
Insulin Resistance	causes	disease	0.65
Alzheimer	activates	disease	0.65
Als	expressed_in	disease	0.65
Als	activates	disease	0.65
ADAM10	inhibits	gene	0.60
SYN1	inhibits	gene	0.60
NEPRILYSIN	activates	gene	0.60
BACE1	inhibits	gene	0.60
GFAP	inhibits	gene	0.60
PLAU	associated_with	gene	0.60
TAU	activates	gene	0.60
AKT	activates	gene	0.60
MAPT	associated_with	gene	0.60
TGFB1	associated_with	gene	0.60
SORL1	interacts_with	gene	0.60
PSEN1	interacts_with	gene	0.60

Incoming (99)

Source	Relation	Type	Str
INSULIN	upregulates	protein	0.80
BACE1	expresses	gene	0.70
BDNF	expresses	gene	0.70
APP	regulates	gene	0.70
CREB	regulates	gene	0.70
GRIN1	regulates	gene	0.70
GRIN2B	regulates	gene	0.70
insulin signaling	upregulates	pathway	0.70
PLAU	associated_with	gene	0.60
BDNF	associated_with	gene	0.60
PSEN1	associated_with	gene	0.60
MAPT	associated_with	gene	0.60
IL6	associated_with	gene	0.60
ACE	associated_with	gene	0.60
HSPG2	associated_with	gene	0.60
PRNP	associated_with	gene	0.60
ABCB1	regulates	gene	0.60
CD68	regulates	gene	0.60
NEURODEGENERATION	activates	gene	0.60
ALZHEIMER'S DISEASE	activates	gene	0.60
metformin	targets	drug	0.60
SORL1	associated_with	gene	0.60
IL1A	associated_with	gene	0.60
IL10	associated_with	gene	0.60
ALZHEIMER'S DISEASE	associated_with	gene	0.60
NGF	activates	gene	0.60
APP	activates	gene	0.60
BDNF	activates	gene	0.60
APOE	activates	gene	0.60
LRP1	activates	gene	0.60
TGFB1	associated_with	gene	0.60
PPAR	activates	gene	0.60
APP	inhibits	gene	0.60
INFLAMMATION	activates	gene	0.60
OXIDATIVE STRESS	activates	gene	0.60
NEURODEGENERATION	regulates	gene	0.60
NEP	activates	gene	0.60
AMYLOID	activates	gene	0.60
APOPTOSIS	activates	gene	0.60
ALZHEIMER	activates	gene	0.60
ACE2	activates	gene	0.60
APP	degrades	gene	0.60
BACE1	degrades	gene	0.60
AΒ	degrades	gene	0.60
AΒ	inhibits	gene	0.60
APOE	enhances	gene	0.60
BACE1	associated_with	gene	0.60
CD36	activates	gene	0.60
ALZHEIMER	associated_with	gene	0.60
NEPRILYSIN	activates	gene	0.60

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Real-time gamma-guided transcranial focused ultrasound targe	0.827	alzheimers	Circuit-level neural dynamics in neurode
miR-33 Antisense Oligonucleotide Hyper-Lipidation Strategy	0.824	molecular-biology	Is APOE4's reduced lipid binding pathoge
ω-3 Docosahexaenoic Acid (DHA) Epoxide Generation via CYP2J2	0.802	lipidomics	Lipid metabolism dysregulation in Alzhei
CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Wind	0.801	neuroimmunology	TREM2 in Alzheimer's Disease: Mechanisms
Lysosomal GBA1 Enhancement via Glucosylceramide Reduction	0.800	neurodegeneration	Test

Competitive APOE4 Domain Stabilization Peptides	0.784	neurodegeneration	APOE4 structural biology and therapeutic
Integrated Biomarker Panel for Therapeutic Window Identifica	0.784	neurodegeneration	What are the precise temporal dynamics o
ASO-mediated reduction of toxic C9orf72 dipeptide repeat pro	0.760	neurodegeneration	Test
C9orf72 Hexanucleotide Repeat Dipeptide Repeat Proteins Inhi	0.738	neurodegeneration	Legacy Pre-Pipeline Hypothesis Import
Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in	0.735	alzheimers	TREM2 agonism vs antagonism in DAM micro
SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduct	0.732	neurodegeneration	How do sphingomyelin/ceramide ratios spe
Antisense Oligonucleotide-Mediated APOE4 Haploinsufficiency	0.720	neurodegeneration	APOE4 targeting in neurodegeneration
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides	0.718	neurodegeneration	Blood-brain barrier transport mechanisms
NRF2 Activation Provides Neuroprotection Across ALS, AD, and	0.710	neurodegeneration	Test Preregistration Analysis
C9orf72 repeat RNA and dipeptide-repeat toxicity in ALS/FTD	0.700	neurodegeneration	Test
Glucosylceramide Accumulation from GCase Deficiency Disrupts	0.700	neurodegeneration	-
H5: C9orf72 DPR Dipeptides Corrupt G3BP1 Condensate Properti	0.698	neurodegeneration	How do pathological stress granules tran
Ganglioside Rebalancing Therapy	0.690	neurodegeneration	Lipid raft composition changes in synapt
GPX4 Selenopeptide Mimetics as Neuroprotective Ferroptosis B	0.680	-	Ferroptosis in ALS and motor neuron dise
Matrix Metalloproteinase-9/TIMP-1 Ratio in CSF Identifies Pr	0.675	-	What blood-brain barrier permeability ch
Axonal Transport Defect: C9orf72 hexanucleotide expansion im	0.660	neurodegeneration	What are the neuron-specific effects of
Parthenolide reduces tonic ADORA2A signaling by lowering inf	0.659	neuropharmacology	How does parthenolide specifically modul
Loss of Homeostatic Epigenetic Identity Reprograms Microglia	0.650	neurodegeneration	What molecular mechanisms drive microgli
DNMT1-Targeting Antisense Oligonucleotide Reset	0.648	neurodegeneration	Epigenetic clocks and biological aging i
Palmitoylethanolamide-Based Endocannabinoid Therapy	0.633	-	Blood-brain barrier tight junction disru
ATXN2 Antisense Oligonucleotides Reduce Dipeptide Repeat Pro	0.630	neurodegeneration	Test
Myelin Sulfatide Restoration	0.623	neurodegeneration	Gene expression changes in aging mouse b
CSF Biomarker-Guided ABCA7 Therapeutic Dosing	0.619	neurodegeneration	Why does the V1613M variant reduce amylo
Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Tar	0.613	neurodegeneration	CRISPR-based therapeutic approaches for
C1q effector output is determined more by binding partner id	0.610	neurodegeneration	Does C1q function differ based on subcel

Mentioning Analyses (1)

Scientific analyses that reference this entity

What are the molecular mechanisms by which GLP-1RAs provide neuroprotective effe

neurodegeneration | 2026-04-14 | 0 hypotheses

Experiments (14)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
GWAS of plasma NfL in East Asian cohort	exploratory	Alzheimer's disease	0.950	0.00	human patients - East Asian co	proposed	N/A
GWAS of plasma pTau217 in East Asian cohort	exploratory	Alzheimer's disease	0.950	0.00	human patients - East Asian co	proposed	N/A
Dairy intake and dementia risk in Malmö Diet and Cancer cohort	clinical	Alzheimer's disease	0.950	0.00	Swedish community-based adults	proposed	N/A
GWAS of plasma pTau181 in East Asian cohort	exploratory	Alzheimer's disease	0.950	0.00	human patients - East Asian co	proposed	N/A
GWAS of plasma GFAP in East Asian cohort	exploratory	Alzheimer's disease	0.950	0.00	human patients - East Asian co	proposed	N/A
KEEPS Continuation: Long-term effects of menopausal hormone therapy on	clinical	Alzheimer's disease	0.950	0.00	recently menopausal women with	proposed	N/A
Autophagy receptor identification for stress granule elimination	exploratory	neurodegenerative diseases	0.900	0.00	cultured cells under arsenite	proposed	N/A
GWAS of composite biomarker score	exploratory	Alzheimer's disease	0.900	0.00	human patients - East Asian co	proposed	N/A
RBG treatment in ApoE-/- atherosclerosis mouse model	validation	atherosclerosis	0.900	0.00	ApoE-/- mice	proposed	N/A
Chi3l1 deletion effects on baseline glial activation in mice	validation	baseline neuroinflammation	0.900	0.00	Chi3l1 knockout mice	proposed	N/A
CHI3L1 variant association with AD progression in human patients	exploratory	Alzheimer's disease	0.850	0.00	human patients	proposed	N/A
APOE4 association with TDP-43 pathology in AD	exploratory	Alzheimer's disease	0.750	0.00	human patients	proposed	N/A
tFUS Targeting EC-II SST Interneurons Restores Hippocampal-Prefrontal	in_vivo	Alzheimer's disease	0.744	0.48	hAPP-J20 mice (n=10/group x 3	abandoned	$110,000
s:** - Biochemical binding assays measuring PROTAC selectivity for APO	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$100,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685]	Litvinchuk A, Suh JH, Guo JL, Lin K, Dav	Neuron	2024	1
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317]	Maxine R Nelson, Peng Liu, Ayushi Agrawa	Nature neuroscience	2023	1
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485]	Serrano-Pozo A, Das S, Hyman BT	Lancet Neurol	2021	1
Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216]	Banik SM, Pedram K, Wisnovsky S, Ahn G,	Nature	2020	1
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456]	Long JM, Holtzman DM	Cell	2019	1
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188]	Cetindag AC, Schipke CG, Esselmann H, Kr	The journal of prevention of A	2026	0
Modulation of apolipoprotein E receptor-2 by ApoE4, amyloid β-peptide, reelin, a [PMID:41858499]	["Barger S", "Moerman-Herzog A"]	Frontiers in molecular neurosc	2026	0
ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in O [PMID:41914296]	Wu S, Han F, Qiao Z, Yuan S, Bian X, Zha	Frontiers in bioscience (Landm	2026	0
CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic [PMID:41812941]	["Wang M", "Niu D", "Zhang Q", "Tang Y",	International journal of biolo	2026	0
Multimodal biomarker AI techniques for early neurocognitive disorder diagnosis: [PMID:41921464]	Catino F, Castellana F, Zupo R, Giannocc	Artificial intelligence in med	2026	0
Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635]	Thedim M, Hu J, Maher M, Wiener-Kronish	Br J Anaesth	2026	0
Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639]	Bae H, Song Z, Ali A, Sasaki T, Tesi N e	Geroscience	2026	0
Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis [PMID:40771159]	Padilla CM, Lafyatis R, Gibson KF, Morse	Arthritis Care Res (Hoboken)	2026	0
Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401]	Stern A, Linial M	Geroscience	2026	0
Obstructive sleep apnea, biomarker profiles, and clinical progression in Parkins [PMID:41499940]	Zhu S, An D, Liu X	Sleep Med	2026	0
Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227]	Samudra N, Vemuri M, Weitlauf J	Curr Opin Obstet Gynecol	2026	0
SuPAR levels are increased in sera of euthymic patients with bipolar disorder an [PMID:41605346]	Kök Kendirlioğlu B, Çörekli Kaymakçı E,	J Affect Disord	2026	0
Chitinase-like Proteins YKL-40 and YKL-39 in Colorectal Cancer. [PMID:41677627]	Ivanova T, Kazakova M, Dikov D, Dzhambov	Cells	2026	0
Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who a [PMID:41689888]	Perry R, Kipps C, Soto Martín ME, Bozzal	J Prev Alzheimers Dis	2026	0
Correction: CHI3L1: An Emerging Player in Neuroinflammation and Neurodegeneratio [PMID:41699333]	Mushtaq Umar; Seh Bilal Ahmad; Khanday F	Molecular Neurobiology	2026	0

Debates (1)

Multi-agent debates referencing this entity

The study demonstrates significant reduction in dementia risk (HR 0.63) with GLP

closed · Rounds: 4 · Score: 0.95 · 2026-04-16

Related Research

Hypotheses and analyses mentioning IDE in their description or question text

IDE

Understanding Entity Pages

Summary

Wiki Pages (6)

IDE Gene - Insulin-Degrading Enzyme

CIDEA — Cell Death-Inducing DFFA-Like Effector A

CIDEC Gene

Insulin-Degrading Enzyme (IDE)

Rifaximin SSD in Dementia Trial (RIDE)

CIDEB — Cell Death-Inducing DFFA-Like Effector B

Pathway Diagram

Outgoing (155)

Incoming (99)

Targeting Hypotheses (30)

Mentioning Analyses (1)

What are the molecular mechanisms by which GLP-1RAs provide neuroprotective effe

Experiments (14)

Related Papers (20)

Debates (1)

The study demonstrates significant reduction in dementia risk (HR 0.63) with GLP

Related Research

Competitive APOE4 Domain Stabilization Peptides

Integrated Biomarker Panel for Therapeutic Window Identification

ASO-mediated reduction of toxic C9orf72 dipeptide repeat proteins in ALS/FTD

C9orf72 Hexanucleotide Repeat Dipeptide Repeat Proteins Inhibit Nucleocytoplasmi

Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in Amyloid Phase, Anta

SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduction and BACE1 Regula

Antisense Oligonucleotide-Mediated APOE4 Haploinsufficiency

Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides

NRF2 Activation Provides Neuroprotection Across ALS, AD, and PD

C9orf72 repeat RNA and dipeptide-repeat toxicity in ALS/FTD

H5: C9orf72 DPR Dipeptides Corrupt G3BP1 Condensate Properties

Ganglioside Rebalancing Therapy

GPX4 Selenopeptide Mimetics as Neuroprotective Ferroptosis Blockade

Matrix Metalloproteinase-9/TIMP-1 Ratio in CSF Identifies Preclinical Tight Junc